SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunicum - ilixadencel in MERECA Phase II - results soon !
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: loparn2/14/2020 5:20:06 AM
   of 17
 
Here is an anonymous person's statistical model simulation of the MERECA study median overall survival outcome.

It predicts a MOS of around 23-29 months for patients with ilixadencel + sunitinib versus 36-48 months for patients with sunitinib alone, with confidence intervals not overlapping. Se figure 7.

It is in line with my own estimation and it would imply a successful MERECA (but I think it is already)

seeking-lambda.com/2020/02/11/beyond-kaplan-meier/
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News